person · Reporting owner

Hernandez Joseph

Disclosed activity across 6 companies

Tapewire entity: 56213
SEC CIK: 0001598384

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Blue Water Acquisition Corp. IVBWIV · Entity 6405	Director · Chief Executive Officer · 10% owner	March 23, 2026	March 24, 2026
CLARUS THERAPEUTICS INCCRXT · Entity 127900	Director · Former 10% owner	September 09, 2021	September 13, 2021
Clarus Therapeutics Holdings, Inc.CRXT · Entity 126356	Director	June 07, 2022	June 09, 2022
ORAGENICS INCOGEN · Entity 8495	10% owner	January 04, 2021	January 26, 2021
Onconetix, Inc.BWV · Entity 8471	Director · CEO · 10% owner	May 09, 2023	May 11, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Blue Water Acquisition Corp. IV

Report date March 23, 2026 · Filed March 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A ordinary sharesSEC Table I · non-derivative	IndirectSee footnote	275,000	Reported balance After 2026-03-23 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-03-23 · Purchase · Acquired 275,000 · Balance 275,000 F1: Reflects the 275,000 private units owned by Blue Water Acquisition IV LLC, the Issuer's sponsor (the "sponsor"). Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $2,750,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein.
Warrants to purchase Class A ordinary sharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.50	IndirectSee footnote	137,500	Reported balance After 2026-03-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-03-23 · Purchase · Acquired 137,500 · Balance 137,500 F1: Reflects the 275,000 private units owned by Blue Water Acquisition IV LLC, the Issuer's sponsor (the "sponsor"). Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $2,750,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein. F2: The warrants included in the private units will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the 275,000 private units owned by Blue Water Acquisition IV LLC, the Issuer's sponsor (the "sponsor"). Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $2,750,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein.

F2: The warrants included in the private units will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation.

CLARUS THERAPEUTICS INC

Report date September 09, 2021 · Filed September 13, 2021

Jointly reported with Blue Water Sponsor LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Indirectsee footnote	1,302,500	Last balance in matching sequence After 2021-09-09 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2021-09-09 · Exercise / conversion · Acquired 1,437,500 · Balance 1,437,500 F1: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date. F4: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Row 2 · 2021-09-09 · Other · Disposed 135,000 · Balance 1,302,500 F3: Represents the transfer of an aggregate of 135,000 shares of common stock held by Blue Water Sponsor LLC (the "Sponsor") to certain noteholders of Clarus, pursuant to that certain share allocation agreement, dated as of September 1, 2021, entered by and among Clarus, the registrant, the Sponsor, certain noteholders and equityholders of Clarus. F4: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
Class B Common StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-09-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-09-09 · Exercise / conversion · Disposed 1,437,500 · Balance 0 F1: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date. F2: As described in the registrant's registration statement on Form S-4 (File No. 333-256116) and the second amended and restated certificate of incorporation of the registrant, which took effect in connection with the closing of the registrant's business combination with Clarus Therapeutics, Inc., a Delaware corporation ("Clarus"), on September 9, 2021, all Class A common stock of the registrant was redesignated as common stock, par value $0.0001 per share. F4: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-09-09	IndirectSee footnote	3,445,000	Reported balance After 2021-09-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-09-09 · Grant · Acquired 3,445,000 · Balance 3,445,000 F5: The Sponsor acquired these warrants for a purchase price of $1.00 per warrant in connection with the initial public offering of the registrant. The warrants could only become eligible for exercise upon consummation of the registrant's initial business combination. Since the exercise of the warrants was contingent upon the closing of the business combination, these warrants were not reported at the time of acquisition. The acquisition is being reported now in connection with the consummation of the registrant's initial business combination. F2: As described in the registrant's registration statement on Form S-4 (File No. 333-256116) and the second amended and restated certificate of incorporation of the registrant, which took effect in connection with the closing of the registrant's business combination with Clarus Therapeutics, Inc., a Delaware corporation ("Clarus"), on September 9, 2021, all Class A common stock of the registrant was redesignated as common stock, par value $0.0001 per share. F4: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date.

F2: As described in the registrant's registration statement on Form S-4 (File No. 333-256116) and the second amended and restated certificate of incorporation of the registrant, which took effect in connection with the closing of the registrant's business combination with Clarus Therapeutics, Inc., a Delaware corporation ("Clarus"), on September 9, 2021, all Class A common stock of the registrant was redesignated as common stock, par value $0.0001 per share.

F3: Represents the transfer of an aggregate of 135,000 shares of common stock held by Blue Water Sponsor LLC (the "Sponsor") to certain noteholders of Clarus, pursuant to that certain share allocation agreement, dated as of September 1, 2021, entered by and among Clarus, the registrant, the Sponsor, certain noteholders and equityholders of Clarus.

F4: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

F5: The Sponsor acquired these warrants for a purchase price of $1.00 per warrant in connection with the initial public offering of the registrant. The warrants could only become eligible for exercise upon consummation of the registrant's initial business combination. Since the exercise of the warrants was contingent upon the closing of the business combination, these warrants were not reported at the time of acquisition. The acquisition is being reported now in connection with the consummation of the registrant's initial business combination.

Clarus Therapeutics Holdings, Inc.

Report date June 07, 2022 · Filed June 09, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,243,266	Reported balance After 2022-06-07 transaction · row 1 1 source row Row 1 · 2022-06-07 · Grant · Acquired 1,922 · Balance 1,243,266 F1: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2032-06-06	Direct	4,805	Reported balance After 2022-06-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-06-07 · Grant · Acquired 4,805 · Balance 4,805 F2: These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	65,000	Reported balance Holding disclosure · report date 2022-06-07 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 65,000 F3: These shares are held by Blue Water Sponsor LLC (the "Sponsor"). Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.

F2: These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.

F3: These shares are held by Blue Water Sponsor LLC (the "Sponsor"). Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

ORAGENICS INC

Report date January 04, 2021 · Filed January 26, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.001 par valueSEC Table I · non-derivative	Direct	0	Ending reported balance After 2021-01-14 transaction · row 8 8 source rows · reconciled sequence Row 1 · 2021-01-04 · Sale · Disposed 176,003 · Balance 4,023,997 F1: The reporting person sold these shares of common stock on the open market. F2: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F3: On January 4, 2021, the reporting person sold 176,003 shares on the open market at $0.52 per share, the market price of the common stock on such date, for total proceeds of $91,521.56. Row 2 · 2021-01-05 · Sale · Disposed 500,000 · Balance 3,523,997 F1: The reporting person sold these shares of common stock on the open market. F2: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F4: On January 5, 2021, the reporting person sold 500,000 shares on the open market at $0.5804 per share, the market price of the common stock on such date, for total proceeds of $290,184.58. Row 3 · 2021-01-06 · Sale · Disposed 1,000,000 · Balance 2,523,997 F1: The reporting person sold these shares of common stock on the open market. F2: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F5: This reflects the weighted average sale price. On January 6, 2021, the reporting person sold a total of 1,000,000 shares for a total of $645,000 on the open market, with the range of prices for such transactions being $0.60 to $0.73 per share. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2021-01-07 · Sale · Disposed 323,997 · Balance 2,200,000 F1: The reporting person sold these shares of common stock on the open market. F2: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F6: On January 7, 2021, the reporting person sold 323,997 shares on the open market at $0.84 per share, the market price of the common stock on such date, for total proceeds of $272,157.48. Row 5 · 2021-01-11 · Sale · Disposed 441,929 · Balance 1,758,071 F1: The reporting person sold these shares of common stock on the open market. F2: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F7: On January 11, 2021, the reporting person sold 441,929 shares on the open market at $0.7710 per share, the market price of the common stock on such date, for total proceeds of $340,710.72. Row 6 · 2021-01-12 · Sale · Disposed 629,707 · Balance 1,128,364 F1: The reporting person sold these shares of common stock on the open market. F2: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F8: This reflects the weighted average sale price. On January 11, 2021, the reporting person sold a total of 629,707 shares for a total of $455,441.30 on the open market, with the range of prices for such transactions being $0.7201 to $0.7501 per share. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Row 7 · 2021-01-13 · Sale · Disposed 257,510 · Balance 870,854 F1: The reporting person sold these shares of common stock on the open market. F2: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F9: On January 13, 2021, the reporting person sold 257,510 shares on the open market at $0.8000 per share, the market price of the common stock on such date, for total proceeds of $205,994.44. Row 8 · 2021-01-14 · Sale · Disposed 870,854 · Balance 0 F1: The reporting person sold these shares of common stock on the open market. F2: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F10: This reflects the weighted average sale price. On January 14, 2021, the reporting person sold a total of 870,854 shares for a total of $859,466.01 on the open market, with the range of prices for such transactions being $0.9602 to $0.1.0068 per share. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person sold these shares of common stock on the open market.

F2: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement.

F3: On January 4, 2021, the reporting person sold 176,003 shares on the open market at $0.52 per share, the market price of the common stock on such date, for total proceeds of $91,521.56.

F4: On January 5, 2021, the reporting person sold 500,000 shares on the open market at $0.5804 per share, the market price of the common stock on such date, for total proceeds of $290,184.58.

F5: This reflects the weighted average sale price. On January 6, 2021, the reporting person sold a total of 1,000,000 shares for a total of $645,000 on the open market, with the range of prices for such transactions being $0.60 to $0.73 per share. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.

F6: On January 7, 2021, the reporting person sold 323,997 shares on the open market at $0.84 per share, the market price of the common stock on such date, for total proceeds of $272,157.48.

F7: On January 11, 2021, the reporting person sold 441,929 shares on the open market at $0.7710 per share, the market price of the common stock on such date, for total proceeds of $340,710.72.

F8: This reflects the weighted average sale price. On January 11, 2021, the reporting person sold a total of 629,707 shares for a total of $455,441.30 on the open market, with the range of prices for such transactions being $0.7201 to $0.7501 per share. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.

F9: On January 13, 2021, the reporting person sold 257,510 shares on the open market at $0.8000 per share, the market price of the common stock on such date, for total proceeds of $205,994.44.

F10: This reflects the weighted average sale price. On January 14, 2021, the reporting person sold a total of 870,854 shares for a total of $859,466.01 on the open market, with the range of prices for such transactions being $0.9602 to $0.1.0068 per share. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.

Onconetix, Inc.

Report date May 09, 2023 · Filed May 11, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,800,351	Reported balance After 2023-05-09 transaction · row 1 1 source row Row 1 · 2023-05-09 · Grant · Acquired 150,000 · Balance 2,800,351 F1: The restricted stock award was granted pursuant to the Blue Water Biotech, Inc. Amended and Restated 2022 Equity Incentive Plan. 50% of the stock award will vest on August 17, 2023; 25% of the award will vest on August 17, 2024; and the remaining 25% of the award will vest on August 18, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock award was granted pursuant to the Blue Water Biotech, Inc. Amended and Restated 2022 Equity Incentive Plan. 50% of the stock award will vest on August 17, 2023; 25% of the award will vest on August 17, 2024; and the remaining 25% of the award will vest on August 18, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Blue Water Acquisition Corp. III

Report date November 25, 2025 · Filed November 28, 2025

Section 16 reporting ended · disclosed 2025-11-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A ordinary sharesSEC Table I · non-derivative	IndirectSee Footnote	430,000	Reported balance After 2025-11-25 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-11-25 · Sale · Disposed 430,000 · Balance 430,000 F4: Represents securities included in the 430,000 Private Placement Units. F1: In connection with the Purchase Agreement, dated as of November 25, 2025, by and among the Issuer, Blue Water Acquisition III LLC (the "Original Sponsor") and Yorkville BW Acquisition Sponsor, LLC (the "New Sponsor"), the Original Sponsor sold to the New Sponsor an aggregate of 6,325,000 Class B ordinary shares (the "Founder Shares") and 430,000 private placement units (the "Private Placement Units"), consisting of 430,000 Class A ordinary shares and 215,000 warrants to purchase Class A ordinary shares of the Issuer (the "Private Placement Warrants"). The New Sponsor purchased the Founder Shares and Private Placement Units for an aggregate purchase price of $7,200,000. F2: The securities are held directly by the Original Sponsor. The Reporting Person is a managing member of the Original Sponsor, therefore, he may be deemed to have beneficial ownership of the securities held directly by the Original Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Class B ordinary sharesSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2025-11-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-11-25 · Other · Disposed 6,325,000 · Balance 0 F3: The Class B ordinary shares have no expiration date and will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis. F1: In connection with the Purchase Agreement, dated as of November 25, 2025, by and among the Issuer, Blue Water Acquisition III LLC (the "Original Sponsor") and Yorkville BW Acquisition Sponsor, LLC (the "New Sponsor"), the Original Sponsor sold to the New Sponsor an aggregate of 6,325,000 Class B ordinary shares (the "Founder Shares") and 430,000 private placement units (the "Private Placement Units"), consisting of 430,000 Class A ordinary shares and 215,000 warrants to purchase Class A ordinary shares of the Issuer (the "Private Placement Warrants"). The New Sponsor purchased the Founder Shares and Private Placement Units for an aggregate purchase price of $7,200,000. F2: The securities are held directly by the Original Sponsor. The Reporting Person is a managing member of the Original Sponsor, therefore, he may be deemed to have beneficial ownership of the securities held directly by the Original Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Warrants to purchase Class A ordinary sharesSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2025-11-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-11-25 · Other · Disposed 215,000 · Balance 0 F4: Represents securities included in the 430,000 Private Placement Units. F5: Each whole Private Placement Warrant entitles the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The Private Placement Warrants will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation. F1: In connection with the Purchase Agreement, dated as of November 25, 2025, by and among the Issuer, Blue Water Acquisition III LLC (the "Original Sponsor") and Yorkville BW Acquisition Sponsor, LLC (the "New Sponsor"), the Original Sponsor sold to the New Sponsor an aggregate of 6,325,000 Class B ordinary shares (the "Founder Shares") and 430,000 private placement units (the "Private Placement Units"), consisting of 430,000 Class A ordinary shares and 215,000 warrants to purchase Class A ordinary shares of the Issuer (the "Private Placement Warrants"). The New Sponsor purchased the Founder Shares and Private Placement Units for an aggregate purchase price of $7,200,000. F2: The securities are held directly by the Original Sponsor. The Reporting Person is a managing member of the Original Sponsor, therefore, he may be deemed to have beneficial ownership of the securities held directly by the Original Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the Purchase Agreement, dated as of November 25, 2025, by and among the Issuer, Blue Water Acquisition III LLC (the "Original Sponsor") and Yorkville BW Acquisition Sponsor, LLC (the "New Sponsor"), the Original Sponsor sold to the New Sponsor an aggregate of 6,325,000 Class B ordinary shares (the "Founder Shares") and 430,000 private placement units (the "Private Placement Units"), consisting of 430,000 Class A ordinary shares and 215,000 warrants to purchase Class A ordinary shares of the Issuer (the "Private Placement Warrants"). The New Sponsor purchased the Founder Shares and Private Placement Units for an aggregate purchase price of $7,200,000.

F2: The securities are held directly by the Original Sponsor. The Reporting Person is a managing member of the Original Sponsor, therefore, he may be deemed to have beneficial ownership of the securities held directly by the Original Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F3: The Class B ordinary shares have no expiration date and will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis.

F4: Represents securities included in the 430,000 Private Placement Units.

F5: Each whole Private Placement Warrant entitles the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The Private Placement Warrants will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 23, 2026 Filed Mar 24, 2026 16:30 UTC	Blue Water Acquisition Corp. IV BWIV · Entity 6405	PurchaseWarrants to purchase Class A ordinary shares · Derivative	137,500	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001493152-26-012371 · ownership.xml · derivative · entry 2 Hernandez Joseph · CIK 0001598384 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 137,500 Underlying: Class A ordinary shares · 137,500 shares Expires not disclosed F1 · price: Reflects the 275,000 private units owned by Blue Water Acquisition IV LLC, the Issuer's sponsor (the "sponsor"). Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $2,750,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein. F2 · derivative.exercise_date: The warrants included in the private units will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation. F2 · derivative.expiration_date: The warrants included in the private units will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation. F1 · ownership.nature: Reflects the 275,000 private units owned by Blue Water Acquisition IV LLC, the Issuer's sponsor (the "sponsor"). Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $2,750,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein. Read SEC document
March 23, 2026 Filed Mar 24, 2026 16:30 UTC	Blue Water Acquisition Corp. IV BWIV · Entity 6405	PurchaseClass A ordinary shares	275,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-26-012371 · ownership.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 275,000 F1 · price: Reflects the 275,000 private units owned by Blue Water Acquisition IV LLC, the Issuer's sponsor (the "sponsor"). Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $2,750,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein. F1 · ownership.nature: Reflects the 275,000 private units owned by Blue Water Acquisition IV LLC, the Issuer's sponsor (the "sponsor"). Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $2,750,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:05 UTC	Blue Water Acquisition Corp. III BLUW · Entity 5827	OtherWarrants to purchase Class A ordinary shares · Derivative	215,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-25-025414 · ownership.xml · derivative · entry 3 Hernandez Joseph · CIK 0001598384 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Class A ordinary shares · 215,000 shares Expires not disclosed F4 · security: Represents securities included in the 430,000 Private Placement Units. F5 · derivative.exercise_price: Each whole Private Placement Warrant entitles the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The Private Placement Warrants will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation. F1 · price: In connection with the Purchase Agreement, dated as of November 25, 2025, by and among the Issuer, Blue Water Acquisition III LLC (the "Original Sponsor") and Yorkville BW Acquisition Sponsor, LLC (the "New Sponsor"), the Original Sponsor sold to the New Sponsor an aggregate of 6,325,000 Class B ordinary shares (the "Founder Shares") and 430,000 private placement units (the "Private Placement Units"), consisting of 430,000 Class A ordinary shares and 215,000 warrants to purchase Class A ordinary shares of the Issuer (the "Private Placement Warrants"). The New Sponsor purchased the Founder Shares and Private Placement Units for an aggregate purchase price of $7,200,000. F5 · derivative.exercise_date: Each whole Private Placement Warrant entitles the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The Private Placement Warrants will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation. F5 · derivative.expiration_date: Each whole Private Placement Warrant entitles the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The Private Placement Warrants will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation. F2 · ownership.nature: The securities are held directly by the Original Sponsor. The Reporting Person is a managing member of the Original Sponsor, therefore, he may be deemed to have beneficial ownership of the securities held directly by the Original Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:05 UTC	Blue Water Acquisition Corp. III BLUW · Entity 5827	OtherClass B ordinary shares · Derivative	6,325,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-25-025414 · ownership.xml · derivative · entry 2 Hernandez Joseph · CIK 0001598384 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 6,325,000 shares Expires not disclosed F3 · derivative.exercise_price: The Class B ordinary shares have no expiration date and will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis. F1 · price: In connection with the Purchase Agreement, dated as of November 25, 2025, by and among the Issuer, Blue Water Acquisition III LLC (the "Original Sponsor") and Yorkville BW Acquisition Sponsor, LLC (the "New Sponsor"), the Original Sponsor sold to the New Sponsor an aggregate of 6,325,000 Class B ordinary shares (the "Founder Shares") and 430,000 private placement units (the "Private Placement Units"), consisting of 430,000 Class A ordinary shares and 215,000 warrants to purchase Class A ordinary shares of the Issuer (the "Private Placement Warrants"). The New Sponsor purchased the Founder Shares and Private Placement Units for an aggregate purchase price of $7,200,000. F3 · derivative.exercise_date: The Class B ordinary shares have no expiration date and will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis. F3 · derivative.expiration_date: The Class B ordinary shares have no expiration date and will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis. F2 · ownership.nature: The securities are held directly by the Original Sponsor. The Reporting Person is a managing member of the Original Sponsor, therefore, he may be deemed to have beneficial ownership of the securities held directly by the Original Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:05 UTC	Blue Water Acquisition Corp. III BLUW · Entity 5827	SaleClass A ordinary shares	430,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-25-025414 · ownership.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 430,000 F4 · security: Represents securities included in the 430,000 Private Placement Units. F1 · price: In connection with the Purchase Agreement, dated as of November 25, 2025, by and among the Issuer, Blue Water Acquisition III LLC (the "Original Sponsor") and Yorkville BW Acquisition Sponsor, LLC (the "New Sponsor"), the Original Sponsor sold to the New Sponsor an aggregate of 6,325,000 Class B ordinary shares (the "Founder Shares") and 430,000 private placement units (the "Private Placement Units"), consisting of 430,000 Class A ordinary shares and 215,000 warrants to purchase Class A ordinary shares of the Issuer (the "Private Placement Warrants"). The New Sponsor purchased the Founder Shares and Private Placement Units for an aggregate purchase price of $7,200,000. F2 · ownership.nature: The securities are held directly by the Original Sponsor. The Reporting Person is a managing member of the Original Sponsor, therefore, he may be deemed to have beneficial ownership of the securities held directly by the Original Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
June 11, 2025 Filed Jun 12, 2025 20:27 UTC	Blue Water Acquisition Corp. III BLUW · Entity 5827	PurchaseWarrants to purchase Class A ordinary shares · Derivative	215,000	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001641172-25-014857 · ownership.xml · derivative · entry 2 Hernandez Joseph · CIK 0001598384 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 215,000 Underlying: Class A ordinary shares · 215,000 shares Expires not disclosed F1 · price: Reflects the 430,000 private units owned by Blue Water Acquisition III LLC, the Issuer's sponsor. Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $4,300,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein. F2 · derivative.exercise_date: The warrants included in the private units will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation. F2 · derivative.expiration_date: The warrants included in the private units will become exercisable at the later of 12 months from the closing of the Issuer's initial public offering and 30 days after the completion of its initial business combination and will expire five years after the completion of the initial business combination or earlier upon redemption or liquidation. F1 · ownership.nature: Reflects the 430,000 private units owned by Blue Water Acquisition III LLC, the Issuer's sponsor. Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $4,300,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein. Read SEC document
June 11, 2025 Filed Jun 12, 2025 20:27 UTC	Blue Water Acquisition Corp. III BLUW · Entity 5827	PurchaseClass A ordinary shares	430,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001641172-25-014857 · ownership.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 430,000 F1 · price: Reflects the 430,000 private units owned by Blue Water Acquisition III LLC, the Issuer's sponsor. Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $4,300,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein. F1 · ownership.nature: Reflects the 430,000 private units owned by Blue Water Acquisition III LLC, the Issuer's sponsor. Each private unit consists of one Class A ordinary share and one-half of one warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The private units were purchased at $10.00 per unit for an aggregate purchase price of $4,300,000. Joseph Hernandez is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Mr. Hernandez disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of his pecuniary interest therein. Read SEC document
May 09, 2023 Filed May 11, 2023 21:22 UTC	Onconetix, Inc. BWV · Entity 8471	GrantCommon Stock	150,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-23-038670 · ownership.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,800,351 F1 · price: The restricted stock award was granted pursuant to the Blue Water Biotech, Inc. Amended and Restated 2022 Equity Incentive Plan. 50% of the stock award will vest on August 17, 2023; 25% of the award will vest on August 17, 2024; and the remaining 25% of the award will vest on August 18, 2025. Read SEC document
August 22, 2022 Filed Aug 22, 2022 21:59 UTC	Onconetix, Inc. BWV · Entity 8471	SaleCommon Stock	30,269	$4.10	$124,205.81	Disclosure SEC source: 0001213900-22-050240 · ownership.xml · nonDerivative · entry 3 Hernandez Joseph · CIK 0001598384 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,650,351 F3 · price: The Common Stock reported herein were sold by the reporting person at a high price of $4.22, a low price of $4.05 and an average price of $4.1034 per share of Common Stock. Upon request, the reporting person will provide details of each sale. Read SEC document
August 19, 2022 Filed Aug 22, 2022 21:59 UTC	Onconetix, Inc. BWV · Entity 8471	SaleCommon Stock	76,841	$4.21	$323,661.98	Disclosure SEC source: 0001213900-22-050240 · ownership.xml · nonDerivative · entry 2 Hernandez Joseph · CIK 0001598384 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,680,620 F2 · price: The Common Stock reported herein were sold by the reporting person at a high price of $4.71, a low price of $4.05 and an average price of $4.2121 per share of Common Stock. Upon request, the reporting person will provide details of each sale. Read SEC document
August 18, 2022 Filed Aug 22, 2022 21:59 UTC	Onconetix, Inc. BWV · Entity 8471	SaleCommon Stock	442,539	$4.96	$2,192,825.00	Disclosure SEC source: 0001213900-22-050240 · ownership.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,757,461 F1 · price: The Common Stock reported herein were sold by the reporting person at a high price of $6.21, a low price of $4.16 and an average price of $4.9551 per share of Common Stock. Upon request, the reporting person will provide details of each sale. Read SEC document
June 07, 2022 Filed Jun 9, 2022 20:02 UTC	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	GrantStock Option (Right to Buy) · Derivative	4,805	$0.00 Strike: $0.43	$0.00	Disclosure SEC source: 0000899243-22-021755 · doc4.xml · derivative · entry 3 Hernandez Joseph · CIK 0001598384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Underlying: Common Stock · 4,805 shares Expires 2032-06-06 F2 · derivative.exercise_date: These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting. Read SEC document
June 07, 2022 Filed Jun 9, 2022 20:02 UTC	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	GrantCommon Stock	1,922	$0.00	$0.00	Disclosure SEC source: 0000899243-22-021755 · doc4.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,243,266 F1 · shares: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting. Read SEC document
May 04, 2022 Filed May 27, 2022 10:42 UTC	Onconetix, Inc. BWV · Entity 8471	GrantStock Option · Derivative	200,000	$0.00 Strike: $6.45	$0.00	Disclosure SEC source: 0001213900-22-029997 · ownership.xml · derivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock, par value $0.00001 per share · 200,000 shares Expires 2032-05-04 F1 · derivative.exercise_date: Stock options (the "Options") were granted to Mr. Hernandez on May 4, 2022. The Options vest and become exercisable as follows (i) 174,972 Options vested immediately upon grant; (ii) 4,171 Options vest at the end of each calendar month from the date of issuance through September 30, 2022 and (iii) the remaining 4,173 Options vest on October 30, 2022. Read SEC document
April 25, 2022 Filed Apr 27, 2022 16:09 UTC	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	GrantWarrants · Derivative	3,445,000	$1.00 Strike: $11.50	$3,445,000.00	Disclosure SEC source: 0001213900-22-021910 · ownership.xml · derivative · entry 3 Hernandez Joseph · CIK 0001598384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,445,000 Underlying: Common Stock · 3,445,000 shares Expires 2026-09-09 F3 · kind: Represents the transfer of an aggregate of 1,237,500 shares of common stock and 3,445,000 warrants held by the Sponsor to Mr. Hernandez, pursuant to that certain share transfer agreement entered by and between the Sponsor and Mr. Hernandez. Mr. Hernandez will be the holder of record of these securities after the transfer. F5 · derivative.underlying: The Sponsor acquired these warrants for a purchase price of $1.00 per warrant in connection with the initial public offering of the registrant. The warrants became eligible for exercise upon consummation of the registrant's initial business combination on September 9, 2021. Each whole warrant is exercisable to purchase one share of the registrant's common stock at an exercise price of $11.50. F5 · ownership.direct: The Sponsor acquired these warrants for a purchase price of $1.00 per warrant in connection with the initial public offering of the registrant. The warrants became eligible for exercise upon consummation of the registrant's initial business combination on September 9, 2021. Each whole warrant is exercisable to purchase one share of the registrant's common stock at an exercise price of $11.50. Read SEC document
April 25, 2022 Filed Apr 27, 2022 16:09 UTC	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	OtherCommon Stock	1,237,500	$0.00	$0.00	Disclosure SEC source: 0001213900-22-021910 · ownership.xml · nonDerivative · entry 2 Hernandez Joseph · CIK 0001598384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241,344 F3 · kind: Represents the transfer of an aggregate of 1,237,500 shares of common stock and 3,445,000 warrants held by the Sponsor to Mr. Hernandez, pursuant to that certain share transfer agreement entered by and between the Sponsor and Mr. Hernandez. Mr. Hernandez will be the holder of record of these securities after the transfer. F4 · balance_after: Represents shares of common stock held directly by Mr. Hernandez, including (1) 1,237,500 shares of common stock transferred from the Sponsor and (2) 3,844 shares of common stock underlying the Restricted Stock Unit granted to Mr. Hernandez under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") on 12/12/2021, which vests in equal annual installments over three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting date. F3 · ownership.direct: Represents the transfer of an aggregate of 1,237,500 shares of common stock and 3,445,000 warrants held by the Sponsor to Mr. Hernandez, pursuant to that certain share transfer agreement entered by and between the Sponsor and Mr. Hernandez. Mr. Hernandez will be the holder of record of these securities after the transfer. F4 · ownership.direct: Represents shares of common stock held directly by Mr. Hernandez, including (1) 1,237,500 shares of common stock transferred from the Sponsor and (2) 3,844 shares of common stock underlying the Restricted Stock Unit granted to Mr. Hernandez under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") on 12/12/2021, which vests in equal annual installments over three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting date. Read SEC document
April 25, 2022 Filed Apr 27, 2022 16:09 UTC	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	OtherCommon Stock	65,000	$0.00	$0.00	Disclosure SEC source: 0001213900-22-021910 · ownership.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 1,237,500 F1 · kind: Represents the transfer of an aggregate of 65,000 shares of common stock held by Blue Water Sponsor LLC (the "Sponsor") to certain affiliates of the Sponsor pursuant to certain share transfer agreements by and between the Sponsor and each transferee. F2 · ownership.nature: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document
December 12, 2021 Filed Dec 14, 2021 19:00 UTC	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	GrantStock Option (Right to Buy) · Derivative	9,610	$0.00 Strike: $4.78	$0.00	Disclosure SEC source: 0000899243-21-048205 · doc4.xml · derivative · entry 3 Hernandez Joseph · CIK 0001598384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,610 Underlying: Common Stock · 9,610 shares Expires 2031-12-11 F3 · derivative.exercise_date: These options were granted under the 2021 Plan and vest in equal annual installments over a period of three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting. Read SEC document
December 12, 2021 Filed Dec 14, 2021 19:00 UTC	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	GrantCommon Stock	3,844	$0.00	$0.00	Disclosure SEC source: 0000899243-21-048205 · doc4.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,844 F1 · shares: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 3,844 shares on 12/12/2021, which vests in equal annual installments over three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting date. Read SEC document
September 09, 2021 Filed Sep 13, 2021 19:29 UTC	CLARUS THERAPEUTICS INC CRXT · Entity 127900	GrantWarrant · Derivative	3,445,000	$1.00 Strike: $11.50	$3,445,000.00	Disclosure SEC source: 0001213900-21-047779 · ownership.xml · derivative · entry 4 Hernandez Joseph · CIK 0001598384 · Director · Former 10% owner Blue Water Sponsor LLC · CIK 0001818124 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,445,000 Underlying: Common Stock · 3,445,000 shares Expires 2026-09-09 F5 · kind: The Sponsor acquired these warrants for a purchase price of $1.00 per warrant in connection with the initial public offering of the registrant. The warrants could only become eligible for exercise upon consummation of the registrant's initial business combination. Since the exercise of the warrants was contingent upon the closing of the business combination, these warrants were not reported at the time of acquisition. The acquisition is being reported now in connection with the consummation of the registrant's initial business combination. F2 · derivative.underlying: As described in the registrant's registration statement on Form S-4 (File No. 333-256116) and the second amended and restated certificate of incorporation of the registrant, which took effect in connection with the closing of the registrant's business combination with Clarus Therapeutics, Inc., a Delaware corporation ("Clarus"), on September 9, 2021, all Class A common stock of the registrant was redesignated as common stock, par value $0.0001 per share. F4 · ownership.nature: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document
September 09, 2021 Filed Sep 13, 2021 19:29 UTC	CLARUS THERAPEUTICS INC CRXT · Entity 127900	Exercise / conversionClass B Common Stock · Derivative	1,437,500	$0.00	$0.00	Disclosure SEC source: 0001213900-21-047779 · ownership.xml · derivative · entry 3 Hernandez Joseph · CIK 0001598384 · Director · Former 10% owner Blue Water Sponsor LLC · CIK 0001818124 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,437,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date. F1 · derivative.exercise_date: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date. F1 · derivative.expiration_date: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date. F2 · derivative.underlying: As described in the registrant's registration statement on Form S-4 (File No. 333-256116) and the second amended and restated certificate of incorporation of the registrant, which took effect in connection with the closing of the registrant's business combination with Clarus Therapeutics, Inc., a Delaware corporation ("Clarus"), on September 9, 2021, all Class A common stock of the registrant was redesignated as common stock, par value $0.0001 per share. F4 · ownership.nature: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document
September 09, 2021 Filed Sep 13, 2021 19:29 UTC	CLARUS THERAPEUTICS INC CRXT · Entity 127900	OtherCommon Stock	135,000	$0.00	$0.00	Disclosure SEC source: 0001213900-21-047779 · ownership.xml · nonDerivative · entry 2 Hernandez Joseph · CIK 0001598384 · Director · Former 10% owner Blue Water Sponsor LLC · CIK 0001818124 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 1,302,500 F3 · kind: Represents the transfer of an aggregate of 135,000 shares of common stock held by Blue Water Sponsor LLC (the "Sponsor") to certain noteholders of Clarus, pursuant to that certain share allocation agreement, dated as of September 1, 2021, entered by and among Clarus, the registrant, the Sponsor, certain noteholders and equityholders of Clarus. F4 · ownership.nature: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document
September 09, 2021 Filed Sep 13, 2021 19:29 UTC	CLARUS THERAPEUTICS INC CRXT · Entity 127900	Exercise / conversionCommon Stock	1,437,500	$0.00	$0.00	Disclosure SEC source: 0001213900-21-047779 · ownership.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director · Former 10% owner Blue Water Sponsor LLC · CIK 0001818124 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 1,437,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date. F4 · ownership.nature: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document
September 09, 2021 Filed Sep 23, 2021 16:10 UTC Amendment	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	GrantWarrant · Derivative	3,445,000	$1.00 Strike: $11.50	$3,445,000.00	Disclosure SEC source: 0001213900-21-049546 · ownership.xml · derivative · entry 4 Hernandez Joseph · CIK 0001598384 · Director · Former 10% owner Blue Water Sponsor LLC · CIK 0001818124 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,445,000 Underlying: Common Stock · 3,445,000 shares Expires 2026-09-09 F5 · kind: The Sponsor acquired these warrants for a purchase price of $1.00 per warrant in connection with the initial public offering of the registrant. The warrants could only become eligible for exercise upon consummation of the registrant's initial business combination. Since the exercise of the warrants was contingent upon the closing of the business combination, these warrants were not reported at the time of acquisition. The acquisition is being reported now in connection with the consummation of the registrant's initial business combination. F2 · derivative.underlying: As described in the registrant's registration statement on Form S-4 (File No. 333-256116) and the second amended and restated certificate of incorporation of the registrant, which took effect in connection with the closing of the registrant's business combination with Clarus Therapeutics, Inc., a Delaware corporation ("Clarus"), on September 9, 2021, all Class A common stock of the registrant was redesignated as common stock, par value $0.0001 per share. F4 · ownership.nature: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document
September 09, 2021 Filed Sep 23, 2021 16:10 UTC Amendment	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	Exercise / conversionClass B Common Stock · Derivative	1,437,500	$0.00	$0.00	Disclosure SEC source: 0001213900-21-049546 · ownership.xml · derivative · entry 3 Hernandez Joseph · CIK 0001598384 · Director · Former 10% owner Blue Water Sponsor LLC · CIK 0001818124 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,437,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date. F1 · derivative.exercise_date: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date. F1 · derivative.expiration_date: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date. F2 · derivative.underlying: As described in the registrant's registration statement on Form S-4 (File No. 333-256116) and the second amended and restated certificate of incorporation of the registrant, which took effect in connection with the closing of the registrant's business combination with Clarus Therapeutics, Inc., a Delaware corporation ("Clarus"), on September 9, 2021, all Class A common stock of the registrant was redesignated as common stock, par value $0.0001 per share. F4 · ownership.nature: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document
September 09, 2021 Filed Sep 23, 2021 16:10 UTC Amendment	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	OtherCommon Stock	135,000	$0.00	$0.00	Disclosure SEC source: 0001213900-21-049546 · ownership.xml · nonDerivative · entry 2 Hernandez Joseph · CIK 0001598384 · Director · Former 10% owner Blue Water Sponsor LLC · CIK 0001818124 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 1,302,500 F3 · kind: Represents the transfer of an aggregate of 135,000 shares of common stock held by Blue Water Sponsor LLC (the "Sponsor") to certain noteholders of Clarus, pursuant to that certain share allocation agreement, dated as of September 1, 2021, entered by and among Clarus, the registrant, the Sponsor, certain noteholders and equityholders of Clarus. F4 · ownership.nature: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document
September 09, 2021 Filed Sep 23, 2021 16:10 UTC Amendment	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	Exercise / conversionCommon Stock	1,437,500	$0.00	$0.00	Disclosure SEC source: 0001213900-21-049546 · ownership.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · Director · Former 10% owner Blue Water Sponsor LLC · CIK 0001818124 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 1,437,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: As described in the registrant's registration statement on Form S-1 (File No. 333-248569) under the heading "Description of Securities - Founder Shares," the shares of Class B common stock were automatically converted into shares of Class A common stock at the time of the registrant's initial business combination on a one-for-one basis, and have no expiration date. F4 · ownership.nature: Mr. Joseph Hernandez, a director and former chief executive officer of the registrant, is the managing member of the Sponsor. Accordingly, Mr. Hernandez may be deemed to have beneficial ownership of such shares. Mr. Hernandez disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document
January 14, 2021 Filed Jan 26, 2021 22:12 UTC	ORAGENICS INC OGEN · Entity 8495	SaleCommon Stock, $.001 par value	870,854	$0.98	$856,484.91	Disclosure SEC source: 0001213900-21-004433 · ownership.xml · nonDerivative · entry 8 Hernandez Joseph · CIK 0001598384 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reporting person sold these shares of common stock on the open market. F2 · shares: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F10 · price: This reflects the weighted average sale price. On January 14, 2021, the reporting person sold a total of 870,854 shares for a total of $859,466.01 on the open market, with the range of prices for such transactions being $0.9602 to $0.1.0068 per share. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 13, 2021 Filed Jan 26, 2021 22:12 UTC	ORAGENICS INC OGEN · Entity 8495	SaleCommon Stock, $.001 par value	257,510	$0.80	$206,008.00	Disclosure SEC source: 0001213900-21-004433 · ownership.xml · nonDerivative · entry 7 Hernandez Joseph · CIK 0001598384 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,854 F1 · kind: The reporting person sold these shares of common stock on the open market. F2 · shares: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F9 · price: On January 13, 2021, the reporting person sold 257,510 shares on the open market at $0.8000 per share, the market price of the common stock on such date, for total proceeds of $205,994.44. Read SEC document
January 12, 2021 Filed Jan 26, 2021 22:12 UTC	ORAGENICS INC OGEN · Entity 8495	SaleCommon Stock, $.001 par value	629,707	$0.73	$460,189.88	Disclosure SEC source: 0001213900-21-004433 · ownership.xml · nonDerivative · entry 6 Hernandez Joseph · CIK 0001598384 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,128,364 F1 · kind: The reporting person sold these shares of common stock on the open market. F2 · shares: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F8 · price: This reflects the weighted average sale price. On January 11, 2021, the reporting person sold a total of 629,707 shares for a total of $455,441.30 on the open market, with the range of prices for such transactions being $0.7201 to $0.7501 per share. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 11, 2021 Filed Jan 26, 2021 22:12 UTC	ORAGENICS INC OGEN · Entity 8495	SaleCommon Stock, $.001 par value	441,929	$0.77	$340,727.26	Disclosure SEC source: 0001213900-21-004433 · ownership.xml · nonDerivative · entry 5 Hernandez Joseph · CIK 0001598384 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,758,071 F1 · kind: The reporting person sold these shares of common stock on the open market. F2 · shares: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F7 · price: On January 11, 2021, the reporting person sold 441,929 shares on the open market at $0.7710 per share, the market price of the common stock on such date, for total proceeds of $340,710.72. Read SEC document
January 07, 2021 Filed Jan 26, 2021 22:12 UTC	ORAGENICS INC OGEN · Entity 8495	SaleCommon Stock, $.001 par value	323,997	$0.84	$272,157.48	Disclosure SEC source: 0001213900-21-004433 · ownership.xml · nonDerivative · entry 4 Hernandez Joseph · CIK 0001598384 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200,000 F1 · kind: The reporting person sold these shares of common stock on the open market. F2 · shares: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F6 · price: On January 7, 2021, the reporting person sold 323,997 shares on the open market at $0.84 per share, the market price of the common stock on such date, for total proceeds of $272,157.48. Read SEC document
January 06, 2021 Filed Jan 26, 2021 22:12 UTC	ORAGENICS INC OGEN · Entity 8495	SaleCommon Stock, $.001 par value	1,000,000	$0.60	$600,000.00	Disclosure SEC source: 0001213900-21-004433 · ownership.xml · nonDerivative · entry 3 Hernandez Joseph · CIK 0001598384 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,523,997 F1 · kind: The reporting person sold these shares of common stock on the open market. F2 · shares: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F5 · price: This reflects the weighted average sale price. On January 6, 2021, the reporting person sold a total of 1,000,000 shares for a total of $645,000 on the open market, with the range of prices for such transactions being $0.60 to $0.73 per share. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 05, 2021 Filed Jan 26, 2021 22:12 UTC	ORAGENICS INC OGEN · Entity 8495	SaleCommon Stock, $.001 par value	500,000	$0.58	$290,200.00	Disclosure SEC source: 0001213900-21-004433 · ownership.xml · nonDerivative · entry 2 Hernandez Joseph · CIK 0001598384 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,523,997 F1 · kind: The reporting person sold these shares of common stock on the open market. F2 · shares: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F4 · price: On January 5, 2021, the reporting person sold 500,000 shares on the open market at $0.5804 per share, the market price of the common stock on such date, for total proceeds of $290,184.58. Read SEC document
January 04, 2021 Filed Jan 26, 2021 22:12 UTC	ORAGENICS INC OGEN · Entity 8495	SaleCommon Stock, $.001 par value	176,003	$0.52	$91,521.56	Disclosure SEC source: 0001213900-21-004433 · ownership.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,023,997 F1 · kind: The reporting person sold these shares of common stock on the open market. F2 · shares: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. F3 · price: On January 4, 2021, the reporting person sold 176,003 shares on the open market at $0.52 per share, the market price of the common stock on such date, for total proceeds of $91,521.56. Read SEC document
December 02, 2020 Filed Dec 7, 2020 11:18 UTC	ORAGENICS INC OGEN · Entity 8495	SaleCommon Stock, $.001 par value	5,000,000	$0.41	$2,051,500.00	Disclosure SEC source: 0001213900-20-041200 · ownership.xml · nonDerivative · entry 1 Hernandez Joseph · CIK 0001598384 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200,000 F1 · shares: On May 1, 2020, the reporting person received 9,200,000 shares of Oragenics, Inc. through a Stock Purchase Agreement. On December 2, 2020, the reporting person sold 5,000,000 of those shares on the open market at $0.4103 per share for total proceeds of $2,051,445.66, the market price of the common stock on such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.